Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Fludarabine PET in Multiple Myeloma
NCT03832127Phase 1Recruiting
- Sponsor
- CHU de Nantes
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-fludarabine in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoint: Sensitivity of 18F-Fludarabine PET. Started Sep 2022; status: recruiting.
02
Drugs
18F-fludarabine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03832127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832127.